

ASX ANNOUNCEMENT

PATENT FOR IMPROVED MIDKINE ANTIBODY ALLOWED IN EUROPE

- **European Patent Office issued intention to grant midkine antibody patent which covers one of the lead drugs in Cellmid's midkine program**
- **This patent provides comprehensive protection over midkine antibodies in several disease settings including cancer, inflammatory diseases and autoimmune conditions**
- **Important milestone in clinical development program for midkine assets**
- **Significant value-add to the midkine patent portfolio for partnering**

SYDNEY, 22 AUGUST 2019: Cellmid Limited (ASX: CDY) is pleased to advise that it has received notification of intention to grant from the European Patent Office for the "Improved midkine antibody" patent in key European territories (EPO Application No. 15849875.8).

This patent family protects the composition of humanised midkine antibodies that recognize regions within the C-domain of the midkine (MK) protein. The patent also protects the use of these humanised midkine antibodies in several disease settings including the diagnosis and treatment of cancer, inflammatory diseases and autoimmune conditions such as multiple sclerosis.

The humanised therapeutic antibody, designated CAB102, covered by this patent is one of the lead drugs in Cellmid's midkine program, consequently this patent adds significant commercial value to the comprehensive intellectual property portfolio around midkine.

The "Improved midkine antibody" patent family complements the already granted Australian, US and European patents entitled "Antibody recognizing C-domain of midkine" (CDY: ASX Announcement, 29 June 2015) and the recently granted US and European patents "Antibody recognizing N-domain of midkine" USPTO 14/004,458 and EPO 12757658.5 (ASX announcement 7 November 2018).

Taken together, these related patents provide comprehensive protection for Cellmid's antibody assets, which are currently developed by its wholly owned subsidiary, Lynamid.

Extensive pre-clinical efficacy testing and characterisation of CAB102 has already been performed (ASX announcement 7 May 2014), including pharmacokinetic and toxicity studies in two mammalian species. Allowing this patent is a significant milestone for the development of CAB102.

The newly granted midkine antibody patents and allied patent families underpin the Company's dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer, chronic inflammation, surgical adhesions as well as functional disorders in T-regulatory cells and activated neutrophil associated with autoimmune diseases.

Recent provisional patent applications for the use of Lynamid's N-domain antibodies are expected to add to the Company's growing portfolio. These applications covering the areas of accelerated bone healing following fractures and a chronic inflammatory heart failure called myocarditis, highlight the potential for further deployment of Lynamid's intellectual property in clinically relevant scenarios.

Cellmid's total midkine patent portfolio currently comprises 59 patents and applications in 12 patent families, including patents covering the use of MK and anti-MK agents for therapeutic purposes in several diseases such as cancer, inflammatory conditions and autoimmune diseases. In addition, the Company also holds patents covering the use of MK as a diagnostic marker in cancer and other disorders, which can be leveraged as a companion diagnostic, potentially accelerating clinical development.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Cellmid's midkine intellectual property assets are developed by its wholly owned subsidiary, Lynamid Limited.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.